RETRACTED: Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase …

R Dummer, P Queirolo, AMA Guijarro, Y Hu… - The Lancet …, 2022 - thelancet.com
Background Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …
被引用次数：45 相关文章

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.

R Dummer, P Queirolo, AG AM, Y Hu, D Wang… - The Lancet …, 2022 - europepmc.org
Background Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …

[引用][C] RETRACTED: Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm …

R Dummer, P Queirolo, AMA Guijarro, Y Hu… - The Lancet …, 2022 - cir.nii.ac.jp
RETRACTED: Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with
CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study | CiNii …

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

R Dummer, P Queirolo… - The lancet …, 2022 - mdanderson.elsevierpure.com
Background: Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …

RETRACTED: Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase …

R Dummer, P Queirolo, AMA Guijarro, Y Hu, D Wang… - 2022 - Elsevier
Background Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

R Dummer, P Queirolo, AM Abajo Guijarro, Y Hu… - Lancet …, 2022 - zora.uzh.ch
Background: Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …

Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study

R Dummer, P Queirolo, AMA Guijarro… - The Lancet …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Targeted therapy and immunotherapy have shown intracranial activity in
melanoma with CNS metastases, but there remains an unmet need, particularly for patients …